Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03298516
Recruitment Status : Completed
First Posted : October 2, 2017
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.